Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Perspective Therapeutics Inc

CATX ✗ NOT COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$3.20

▲ +3.23%

Market Cap $365.29M · Vol 135.72K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$365.29M

Small Cap

Div Yield

N/A

EPS Growth

+23.87%

YoY

RSI (14)

69.00

Momentum

Beta

1.80

vs Market

52W High

$6.15

47.97% below

52W Low

$1.97

62.85% above

Volume

135.72K

Avg 196.65K

P/B

0.99

Price-to-book

ROE

-41.44%

Return on equity

Free Float

89.20%

Public shares

Shariah Compliance8 STANDARDS

✗ Perspective Therapeutics Inc (CATX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CATX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.67%

+4.92%

-17.10%

-31.91%

YTD

+16.36%

-17.95%

-29.38%

-50.40%

Financials & Valuation

TTM · Annual

Total Revenue	$884.00K
Net Income	$-103,635,000.00
Revenue Growth (YoY)	-72.07%
Gross Margin	100.00%
Operating Margin	-12,846.61%
Net Profit Margin	-11,723.42%
ROE	-41.44%
ROA · ROIC	-34.35% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	229.62
P/B	0.99
P/FCF	N/A
EPS Growth	+23.87%
Outstanding Shares	114.15M

Technical Indicators

50-Day SMA	$3.08
200-Day SMA	$3.51
RSI (14)	69.00
Beta	1.80
52-Week High	$6.15
52-Week Low	$1.97

Volume Today	135.72K
Avg Daily Volume (30D)	196.65K
Relative Volume	0.69x
Volatility (10D)	45.87
Volatility (30D)	54.45
Free Float	89.20%

Analyst Consensus

BUY

Current Price $3.20

Mean Target $12.57

52W Low$1.97 52W High$6.15

Current

Target

$1.97 $6.15

Current Analyst target

+292.86% upside potential · 15 analysts

Identifiers

ExchangeNYSE American

FIGIBBG001S5Q300

ISINUS46489V3024

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.